Jan-Jacob Schuringa

646 total citations
8 papers, 571 citations indexed

About

Jan-Jacob Schuringa is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Jan-Jacob Schuringa has authored 8 papers receiving a total of 571 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 4 papers in Molecular Biology and 4 papers in Cancer Research. Recurrent topics in Jan-Jacob Schuringa's work include Cytokine Signaling Pathways and Interactions (7 papers), NF-κB Signaling Pathways (3 papers) and Melanoma and MAPK Pathways (3 papers). Jan-Jacob Schuringa is often cited by papers focused on Cytokine Signaling Pathways and Interactions (7 papers), NF-κB Signaling Pathways (3 papers) and Melanoma and MAPK Pathways (3 papers). Jan-Jacob Schuringa collaborates with scholars based in Netherlands, United Kingdom and United States. Jan-Jacob Schuringa's co-authors include Edo Vellenga, W. Kruijer, Albertus T.J. Wierenga, Hein Schepers, Wim H.A. Dokter, Lodewijk V. Dekker, Luigi J.C. Jonk, Joost H.A. Martens and Guoqiang Yi and has published in prestigious journals such as Journal of Biological Chemistry, Blood and Biochemical Journal.

In The Last Decade

Jan-Jacob Schuringa

8 papers receiving 553 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jan-Jacob Schuringa Netherlands 7 375 293 174 115 72 8 571
Daniela Baus Germany 6 361 1.0× 367 1.3× 182 1.0× 128 1.1× 125 1.7× 8 682
Aradhana Rani United Kingdom 11 255 0.7× 269 0.9× 151 0.9× 156 1.4× 42 0.6× 15 592
Elsie White United States 7 187 0.5× 443 1.5× 83 0.5× 153 1.3× 34 0.5× 7 613
Anna Dąbrowska‐Iwanicka Poland 9 152 0.4× 177 0.6× 74 0.4× 82 0.7× 80 1.1× 26 442
Thomas Bittorf Germany 15 228 0.6× 287 1.0× 128 0.7× 33 0.3× 47 0.7× 26 593
Haifeng Bao United States 10 201 0.5× 172 0.6× 83 0.5× 48 0.4× 29 0.4× 20 432
Claudia Gerhartz Germany 10 662 1.8× 341 1.2× 413 2.4× 117 1.0× 53 0.7× 11 884
Lu Yue China 17 227 0.6× 627 2.1× 71 0.4× 234 2.0× 66 0.9× 34 866
Shuangwei Li United States 12 194 0.5× 535 1.8× 230 1.3× 76 0.7× 49 0.7× 17 704
Sarah Dewilde Italy 6 249 0.7× 182 0.6× 150 0.9× 61 0.5× 61 0.8× 8 390

Countries citing papers authored by Jan-Jacob Schuringa

Since Specialization
Citations

This map shows the geographic impact of Jan-Jacob Schuringa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan-Jacob Schuringa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan-Jacob Schuringa more than expected).

Fields of papers citing papers by Jan-Jacob Schuringa

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan-Jacob Schuringa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan-Jacob Schuringa. The network helps show where Jan-Jacob Schuringa may publish in the future.

Co-authorship network of co-authors of Jan-Jacob Schuringa

This figure shows the co-authorship network connecting the top 25 collaborators of Jan-Jacob Schuringa. A scholar is included among the top collaborators of Jan-Jacob Schuringa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan-Jacob Schuringa. Jan-Jacob Schuringa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
2.
Schuringa, Jan-Jacob, et al.. (2001). c-Jun AND c-Fos COOPERATE WITH STAT3 IN IL-6-INDUCED TRANSACTIVATION OF THE IL-6 RESPONSE ELEMENT (IRE). Cytokine. 14(2). 78–87. 63 indexed citations
3.
Schuringa, Jan-Jacob, Lodewijk V. Dekker, Edo Vellenga, & W. Kruijer. (2001). Sequential Activation of Rac-1, SEK-1/MKK-4, and Protein Kinase Cδ Is Required for Interleukin-6-induced STAT3 Ser-727 Phosphorylation and Transactivation. Journal of Biological Chemistry. 276(29). 27709–27715. 73 indexed citations
4.
Schuringa, Jan-Jacob, Hein Schepers, Edo Vellenga, & W. Kruijer. (2001). Ser727‐dependent transcriptional activation by association of p300 with STAT3 upon IL‐6 stimulation. FEBS Letters. 495(1-2). 71–76. 107 indexed citations
5.
Schuringa, Jan-Jacob, Luigi J.C. Jonk, Wim H.A. Dokter, Edo Vellenga, & W. Kruijer. (2000). Interleukin-6-induced STAT3 transactivation and Ser727 phosphorylation involves Vav, Rac-1 and the kinase SEK-1/MKK-4 as signal transduction components. Biochemical Journal. 347(1). 89–96. 91 indexed citations
6.
7.
Schuringa, Jan-Jacob, Albertus T.J. Wierenga, W. Kruijer, & Edo Vellenga. (2000). Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6. Blood. 95(12). 3765–3770. 44 indexed citations
8.
Schuringa, Jan-Jacob, Albertus T.J. Wierenga, W. Kruijer, & Edo Vellenga. (2000). Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6. Blood. 95(12). 3765–3770. 160 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026